Peter A Campochiaro

List of Publications by Year in Descending Order

280 papers	23,822 citations	82 h-index	145 g-index
287 ext. papers	26,524 ext. citations	7.4 avg, IF	6.78 L-index

#	Paper	IF	Citations
280	Oxidative stress-induced alterations in retinal glucose metabolism in Retinitis Pigmentosa.. *Free Radical Biology and Medicine*, **2022**, 181, 143-153	7.8	0
279	Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture **2021**, 62, 26		1
278	Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases. *Progress in Retinal and Eye Research*, **2021**, 83, 100921	20.5	24
277	Comment on "Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases". *Eye*, **2021**, 35, 1024-1025	4.4	
276	Locus-Level Changes in Macular Sensitivity in Patients with Retinitis Pigmentosa Treated with Oral N-acetylcysteine. *American Journal of Ophthalmology*, **2021**, 221, 105-114	4.9	5
275	Proteosomal degradation impairs transcytosis of AAV vectors from suprachoroidal space to retina. *Gene Therapy*, **2021**,	4	1
274	Using crowdsourcing to understand patients attitudes toward a clinical trial for retinitis pigmentosa requiring 4 years of participation. *Ophthalmic Genetics*, **2021**, 1-6	1.2	
273	The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. *Current Neuropharmacology*, **2021**, 19, 1202-1224	7.6	6
272	Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. *Ophthalmology*, **2021**,	7.3	22
271	Retinal vascular occlusions. *Lancet, The*, **2020**, 396, 1927-1940	40	21
270	Suprachoroidal gene transfer with nonviral nanoparticles. *Science Advances*, **2020**, 6,	14.3	24
269	Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles. *Nature Communications*, **2020**, 11, 694	17.4	24
268	Sustained delivery of acriflavine from the suprachoroidal space provides long term suppression of choroidal neovascularization. *Biomaterials*, **2020**, 243, 119935	15.6	12
267	Hepatocyte growth factor is upregulated in ischemic retina and contributes to retinal vascular leakage and neovascularization. *FASEB BioAdvances*, **2020**, 2, 219-233	2.8	4
266	Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial. *Journal of Clinical Investigation*, **2020**, 130, 1527-1541	15.9	30
265	Fibulin-7 C-terminal fragment and its active synthetic peptide suppress choroidal and retinal neovascularization. *Microvascular Research*, **2020**, 129, 103986	3.7	2
264	Suppression of Ocular Vascular Inflammation through Peptide-Mediated Activation of Angiopoietin-Tie2 Signaling. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4

263	Structure-Guided Molecular Engineering of a Vascular Endothelial Growth Factor Antagonist to Treat Retinal Diseases. *Cellular and Molecular Bioengineering*, **2020**, 13, 405-418	3.9	0
262	Gelling hypotonic polymer solution for extended topical drug delivery to the eye. *Nature Biomedical Engineering*, **2020**, 4, 1053-1062	19	33
261	A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular Neovascularization. *Cell Reports*, **2019**, 29, 62-75.e7	10.6	15
260	Classification of disease severity in retinitis pigmentosa. *British Journal of Ophthalmology*, **2019**, 103, 1595-1599	5.5	12
259	The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial. *Ophthalmology*, **2019**, 126, 1141-1154	7.3	128
258	Loss of Peak Vision in Retinal Vein Occlusion Patients Treated for Macular Edema. *American Journal of Ophthalmology*, **2019**, 205, 17-26	4.9	13
257	Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization. *Acta Biomaterialia*, **2019**, 97, 451-460	10.8	9
256	A collagen IV-derived peptide disrupts 51 integrin and potentiates Ang2/Tie2 signaling. *JCI Insight*, **2019**, 4,	9.9	23
255	AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. *Journal of Clinical Investigation*, **2019**, 129, 4901-4911	15.9	59
254	Low risk to retina from sustained suppression of VEGF. *Journal of Clinical Investigation*, **2019**, 129, 3029-3031	15.9	6
253	Reply. *Ophthalmology*, **2019**, 126, e88-e89	7.3	
252	Metipranolol promotes structure and function of retinal photoreceptors in the rd10 mouse model of human retinitis pigmentosa. *Journal of Neurochemistry*, **2019**, 148, 307-318	6	8
251	Shortest Distance From Fovea to Subfoveal Hemorrhage Border Is Important in Patients With Neovascular Age-related Macular Degeneration. *American Journal of Ophthalmology*, **2018**, 189, 86-95	4.9	4
250	Progression of Retinitis Pigmentosa as Measured on Microperimetry: The PREP-1 Study. *Ophthalmology Retina*, **2018**, 2, 502-507	3.8	14
249	AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration. *Molecular Therapy*, **2018**, 26, 542-549	11.7	26
248	The mechanism of cone cell death in Retinitis Pigmentosa. *Progress in Retinal and Eye Research*, **2018**, 62, 24-37	20.5	140
247	Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study. *Ophthalmology Retina*, **2018**, 2, 320-328	3.8	39
246	Mousetap, a Novel Technique to Collect Uncontaminated Vitreous or Aqueous and Expand Usefulness of Mouse Models. *Scientific Reports*, **2018**, 8, 6371	4.9	9

245	VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models. *JCI Insight*, **2018**, 3,	9.9	15
244	Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection **2018**, 59, 5266-5276		17
243	Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage. *Science Translational Medicine*, **2017**, 9,	17.5	29
242	Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy. *Ophthalmology*, **2017**, 124, 440-449	7.3	39
241	Increased Frequency of Topical Steroids Provides Benefit in Patients With Recalcitrant Postsurgical Macular Edema. *American Journal of Ophthalmology*, **2017**, 178, 163-175	4.9	9
240	Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. *Lancet, The*, **2017**, 390, 50-61	40	124
239	The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization. *Journal of Molecular Medicine*, **2017**, 95, 417-429	5.5	24
238	Systematic Functional Testing of Rare Variants: Contributions of CFI to Age-Related Macular Degeneration **2017**, 58, 1570-1576		5
237	The Nicotinic Cholinergic Pathway Contributes to Retinal Neovascularization in a Mouse Model of Retinopathy of Prematurity **2017**, 58, 1296-1303		4
236	Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration. *Ophthalmology Retina*, **2017**, 1, 474-485	3.8	42
235	Ocular gene therapy for neovascular AMD: a new era? - AuthorsQreply. *Lancet, The*, **2017**, 390, 2140	40	1
234	Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study. *Human Gene Therapy*, **2017**, 28, 99-111	4.8	119
233	Reversible retinal vessel closure from VEGF-induced leukocyte plugging. *JCI Insight*, **2017**, 2,	9.9	35
232	Reply. *American Journal of Ophthalmology*, **2016**, 170, 245-246	4.9	1
231	Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease: From Bench to Bedside. *Ophthalmology*, **2016**, 123, S78-S88	7.3	73
230	Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema. *Current Diabetes Reports*, **2016**, 16, 126	5.6	43
229	Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. *Ophthalmology*, **2016**, 123, 330-336	7.3	140
228	Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion. *Ophthalmology*, **2016**, 123, 625-34.e1	7.3	46

227	A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. *Nature Genetics*, **2016**, 48, 134-43	36.3	769
226	Reply. *American Journal of Ophthalmology*, **2016**, 161, 216-7	4.9	
225	Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials. *Ophthalmic Surgery Lasers and Imaging Retina*, **2016**, 47, 426-35	1.4	25
224	Pro-permeability Factors in Diabetic Macular Edema; the Diabetic Macular Edema Treated With Ozurdex Trial. *American Journal of Ophthalmology*, **2016**, 168, 13-23	4.9	50
223	Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression. *Ophthalmology*, **2016**, 123, 1722-1730	7.3	75
222	Reply. *Ophthalmology*, **2016**, 123, e33-4	7.3	
221	Reply. *Ophthalmology*, **2016**, 123, e60-1	7.3	1
220	Molecular pathogenesis of retinal and choroidal vascular diseases. *Progress in Retinal and Eye Research*, **2015**, 49, 67-81	20.5	268
219	Pro-Permeability Factors After Dexamethasone Implant in Retinal Vein Occlusion; the Ozurdex for Retinal Vein Occlusion (ORVO) Study. *American Journal of Ophthalmology*, **2015**, 160, 313-321.e19	4.9	28
218	Is There Excess Oxidative Stress and Damage in Eyes of Patients with Retinitis Pigmentosa?. *Antioxidants and Redox Signaling*, **2015**, 23, 643-8	8.4	80
217	Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. *Ophthalmology*, **2015**, 122, 538-44	7.3	160
216	Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes. *American Journal of Ophthalmology*, **2015**, 159, 9-19.e1-2	4.9	36
215	Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. *Ophthalmology*, **2015**, 122, 545-54	7.3	63
214	Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial. *Ophthalmology*, **2015**, 122, 1426-37	7.3	78
213	Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. *Ophthalmology*, **2014**, 121, 1892-903	7.3	109
212	Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema. *Ophthalmology*, **2014**, 121, 2237-46	7.3	24
211	Lysosomal-mediated waste clearance in retinal pigment epithelial cells is regulated by CRYBA1/βA3/A1-crystallin via V-ATPase-MTORC1 signaling. *Autophagy*, **2014**, 10, 480-96	10.2	84
210	Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. *Ophthalmology*, **2014**, 121, 2432-42	7.3	54

209	Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. *Ophthalmology*, **2014**, 121, 209-219	7.3	225
208	Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. *Angiogenesis*, **2014**, 17, 553-62	10.6	45
207	Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. *Journal of Clinical Investigation*, **2014**, 124, 4564-76	15.9	140
206	Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. *Ophthalmology*, **2014**, 121, 1783-9	7.3	130
205	Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. *Ophthalmology*, **2013**, 120, 795-802	7.3	165
204	Sustained delivery of a HIF-1 antagonist for ocular neovascularization. *Journal of Controlled Release* , **2013**, 172, 625-33	11.7	47
203	Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. *American Journal of Ophthalmology*, **2013**, 155, 697-704, 704.e1-2	4.9	86
202	Suppression of GLUT1; a new strategy to prevent diabetic complications. *Journal of Cellular Physiology*, **2013**, 228, 251-7	7	39
201	Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. *Biomaterials*, **2013**, 34, 7544-51	15.6	41
200	Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. *Ophthalmology*, **2013**, 120, 583-587	7.3	90
199	Ocular neovascularization. *Journal of Molecular Medicine*, **2013**, 91, 311-21	5.5	244
198	Seven new loci associated with age-related macular degeneration. *Nature Genetics*, **2013**, 45, 433-9, 439e1-2	36.3	577
197	A functional variant in the CFI gene confers a high risk of age-related macular degeneration. *Nature Genetics*, **2013**, 45, 813-7	36.3	134
196	Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. *American Journal of Ophthalmology*, **2013**, 156, 693-705	4.9	70
195	Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit **2013**, 54, 503-11		16
194	Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration. *Journal of Ocular Pharmacology and Therapeutics*, **2012**, 28, 581-8	2.6	18
193	Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. *Ophthalmology*, **2012**, 119, 802-9	7.3	323
192	Long-term expression of glial cell line-derived neurotrophic factor slows, but does not stop retinal degeneration in a model of retinitis pigmentosa. *Journal of Neurochemistry*, **2012**, 122, 1047-53	6	23

191	Anti-vascular endothelial growth factor treatment for retinal vein occlusions. *Ophthalmologica*, **2012**, 227 Suppl 1, 30-5	3.7	49
190	Injury-independent induction of reactive gliosis in retina by loss of function of the LIM homeodomain transcription factor Lhx2. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 4657-62	11.5	58
189	Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. *Ophthalmology*, **2011**, 118, 626-635.e2	7.3	288
188	Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. *Ophthalmology*, **2011**, 118, 1594-602	7.3	358
187	Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. *Ophthalmology*, **2011**, 118, 2041-9	7.3	377
186	Constituents of bile, bilirubin and TUDCA, protect against oxidative stress-induced retinal degeneration. *Journal of Neurochemistry*, **2011**, 116, 144-53	6	72
185	Overexpression of SOD in retina: need for increase in H2O2-detoxifying enzyme in same cellular compartment. *Free Radical Biology and Medicine*, **2011**, 51, 1347-54	7.8	63
184	N-Acetylcysteine promotes long-term survival of cones in a model of retinitis pigmentosa. *Journal of Cellular Physiology*, **2011**, 226, 1843-9	7	72
183	Gene transfer for neovascular age-related macular degeneration. *Human Gene Therapy*, **2011**, 22, 523-9	4.8	22
182	Vascular cell-adhesion molecule-1 plays a central role in the proangiogenic effects of oxidative stress. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 14614-9	11.5	36
181	A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. *Nature Genetics*, **2011**, 43, 1232-6	36.3	251
180	Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. *Human Molecular Genetics*, **2011**, 20, 3699-709	5.6	205
179	Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. *FASEB Journal*, **2010**, 24, 1759-67	0.9	88
178	The complexity of animal model generation for complex diseases. *JAMA - Journal of the American Medical Association*, **2010**, 303, 657-8	27.4	1
177	Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC). *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 7395-400	11.5	345
176	Genetic and functional dissection of HTRA1 and LOC387715 in age-related macular degeneration. *PLoS Genetics*, **2010**, 6, e1000836	6	82
175	Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. *Ophthalmology*, **2010**, 117, 1393-9.e3	7.3	122
174	Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. *Ophthalmology*, **2010**, 117, 1102-1112.e1	7.3	625

173	Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. *Ophthalmology*, **2010**, 117, 1124-1133.e1	7.3	612
172	Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. *Ophthalmology*, **2010**, 117, 2387-2394.e1-5	7.3	59
171	Topical mecamylamine for diabetic macular edema. *American Journal of Ophthalmology*, **2010**, 149, 839-51.e1	4.9	22
170	Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 7401-6	11.5	417
169	Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. *Journal of Cellular Physiology*, **2010**, 224, 262-72	7	35
168	Agents that bind annexin A2 suppress ocular neovascularization. *Journal of Cellular Physiology*, **2010**, 225, 855-64	7	21
167	Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in retinitis pigmentosa. *Molecular Therapy*, **2009**, 17, 778-86	11.7	93
166	Equine infectious anemia viral vector-mediated codelivery of endostatin and angiostatin driven by retinal pigmented epithelium-specific VMD2 promoter inhibits choroidal neovascularization. *Human Gene Therapy*, **2009**, 20, 31-9	4.8	35
165	Increased expression of glutathione peroxidase 4 strongly protects retina from oxidative damage. *Antioxidants and Redox Signaling*, **2009**, 11, 715-24	8.4	72
164	ADAM9 is involved in pathological retinal neovascularization. *Molecular and Cellular Biology*, **2009**, 29, 2694-703	4.8	74
163	Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. *Journal of Cellular Physiology*, **2009**, 218, 192-8	7	78
162	NADPH oxidase plays a central role in cone cell death in retinitis pigmentosa. *Journal of Neurochemistry*, **2009**, 110, 1028-37	6	100
161	Oxidative stress promotes ocular neovascularization. *Journal of Cellular Physiology*, **2009**, 219, 544-52	7	99
160	Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. *Ophthalmology*, **2009**, 116, 2175-81.e1	7.3	272
159	A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. *Ophthalmology*, **2009**, 116, 2141-8.e1	7.3	81
158	Monitoring ocular drug therapy by analysis of aqueous samples. *Ophthalmology*, **2009**, 116, 2158-64	7.3	57
157	Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. *Ophthalmology*, **2009**, 116, 1748-54	7.3	33
156	BEST1 expression in the retinal pigment epithelium is modulated by OTX family members. *Human Molecular Genetics*, **2009**, 18, 128-41	5.6	37

155	Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. *JAMA Ophthalmology*, **2009**, 127, 494-9		67
154	Blockade of neuronal nitric oxide synthase reduces cone cell death in a model of retinitis pigmentosa. *Free Radical Biology and Medicine*, **2008**, 45, 905-12	7.8	60
153	Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. *Molecular Therapy*, **2008**, 16, 791-9	11.7	253
152	Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration. *American Journal of Ophthalmology*, **2008**, 145, 257-266	4.9	25
151	Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration. *Journal of Medicinal Chemistry*, **2008**, 51, 1546-59	8.3	41
150	Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. *New England Journal of Medicine*, **2008**, 359, 1456-63	59.2	180
149	Trans-scleral delivery of antiangiogenic proteins. *Journal of Ocular Pharmacology and Therapeutics*, **2008**, 24, 70-9	2.6	27
148	An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization. *FASEB Journal*, **2008**, 22, 2775-83	0.9	28
147	Mecamylamine suppresses Basal and nicotine-stimulated choroidal neovascularization. *Investigative Ophthalmology and Visual Science*, **2008**, 49, 1705-11		50
146	MicroRNAs regulate ocular neovascularization. *Molecular Therapy*, **2008**, 16, 1208-16	11.7	179
145	Studies on Retinal and Retinal Pigment Epithelial Gene Expression. *Novartis Foundation Symposium*, **2008**, 131-146		
144	Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. *Journal of Cellular Physiology*, **2008**, 216, 29-37	7	59
143	Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. *Journal of Cellular Physiology*, **2008**, 217, 13-22	7	56
142	Ocular Neovascularization **2008**, 517-531		3
141	Molecular targets for retinal vascular diseases. *Journal of Cellular Physiology*, **2007**, 210, 575-81	7	37
140	Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. *Journal of Cellular Physiology*, **2007**, 213, 809-15	7	197
139	Seeing the light: new insights into the molecular pathogenesis of retinal diseases. *Journal of Cellular Physiology*, **2007**, 213, 348-54	7	11
138	Increased expression of glial cell line-derived neurotrophic factor protects against oxidative damage-induced retinal degeneration. *Journal of Neurochemistry*, **2007**, 103, 1041-52	6	33

137	TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. *Journal of Neuroimmunology*, **2007**, 182, 73-9	3.5	57
136	Protein transport to choroid and retina following periocular injection: theoretical and experimental study. *Annals of Biomedical Engineering*, **2007**, 35, 615-30	4.7	21
135	VMD2 promoter requires two proximal E-box sites for its activity in vivo and is regulated by the MITF-TFE family. *Journal of Biological Chemistry*, **2007**, 282, 1838-50	5.4	34
134	Differential sensitivity of cones to iron-mediated oxidative damage. *Investigative Ophthalmology and Visual Science*, **2007**, 48, 438-45		53
133	Oxidative stress modulates complement factor H expression in retinal pigmented epithelial cells by acetylation of FOXO3. *Journal of Biological Chemistry*, **2007**, 282, 22414-25	5.4	88
132	Gene therapy for ocular neovascularization. *Current Gene Therapy*, **2007**, 7, 25-33	4.3	24
131	Vegf or EphA2 antisense polyamide-nucleic acids; vascular localization and suppression of retinal neovascularization. *Molecular Therapy*, **2007**, 15, 1924-30	11.7	7
130	Intraobserver repeatability of automated versus adjusted optical coherence tomography measurements in patients with neovascular age-related macular degeneration. *Ophthalmologica*, **2007**, 221, 227-32	3.7	9
129	In vivo immunostaining demonstrates macrophages associate with growing and regressing vessels. *Investigative Ophthalmology and Visual Science*, **2007**, 48, 4335-41		56
128	Ocular gene transfer with self-complementary AAV vectors. *Investigative Ophthalmology and Visual Science*, **2007**, 48, 3324-8		42
127	The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. *FASEB Journal*, **2007**, 21, 3219-30	0.9	119
126	Gene transfer of an engineered zinc finger protein enhances the anti-angiogenic defense system. *Molecular Therapy*, **2007**, 15, 1917-23	11.7	15
125	Impact of optical coherence tomography on surgical decision making for epiretinal membranes and vitreomacular traction. *Retina*, **2007**, 27, 552-6	3.6	29
124	Targeted pharmacotherapy of retinal diseases with ranibizumab. *Drugs of Today*, **2007**, 43, 529-37	2.5	26
123	Retinal degeneration from oxidative damage. *Free Radical Biology and Medicine*, **2006**, 40, 660-9	7.8	76
122	Effects of different types of oxidative stress in RPE cells. *Journal of Cellular Physiology*, **2006**, 206, 119-25		84
121	Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. *Journal of Cellular Physiology*, **2006**, 206, 749-58	7	83
120	Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies. *Journal of Cellular Physiology*, **2006**, 207, 407-12	7	53

119	Recombinant non-collagenous domain of alpha2(IV) collagen causes involution of choroidal neovascularization by inducing apoptosis. *Journal of Cellular Physiology*, **2006**, 208, 161-6	7	12
118	Superoxide dismutase 1 protects retinal cells from oxidative damage. *Journal of Cellular Physiology*, **2006**, 208, 516-26	7	71
117	Reduction of p66Shc suppresses oxidative damage in retinal pigmented epithelial cells and retina. *Journal of Cellular Physiology*, **2006**, 209, 996-1005	7	31
116	Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. *Molecular Pharmacology*, **2006**, 69, 1820-8	4.3	72
115	Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. *FASEB Journal*, **2006**, 20, 723-5	0.9	84
114	Antioxidants reduce cone cell death in a model of retinitis pigmentosa. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 11300-5	11.5	321
113	Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. *American Journal of Ophthalmology*, **2006**, 142, 961-9	4.9	302
112	Trans-scleral delivery of polyamine analogs for ocular neovascularization. *Experimental Eye Research*, **2006**, 83, 1260-7	3.7	20
111	A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. *Ophthalmology*, **2006**, 113, 1522.e1-1522.e14	7.3	114
110	Dynamic and quantitative analysis of choroidal neovascularization by fluorescein angiography. *Investigative Ophthalmology and Visual Science*, **2006**, 47, 5460-8		25
109	Delivery from episcleral exoplants. *Investigative Ophthalmology and Visual Science*, **2006**, 47, 4532-9		48
108	The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. *Investigative Ophthalmology and Visual Science*, **2006**, 47, 2135-40		76
107	Ocular versus extraocular neovascularization: mirror images or vague resemblances. *Investigative Ophthalmology and Visual Science*, **2006**, 47, 462-74		39
106	Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. *Human Gene Therapy*, **2006**, 17, 167-76	4.8	286
105	The impact of optical coherence tomography on surgical decision making in epiretinal membrane and vitreomacular traction. *Transactions of the American Ophthalmological Society*, **2006**, 104, 161-6		17
104	Vasohibin is Up-regulated by VEGF in the Retina and Suppresses VEGF receptor 2 and Retinal Neovascularization. *FASEB Journal*, **2006**, 20, A716	0.9	1
103	Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. *Human Gene Therapy*, **2005**, 16, 473-8	4.8	63
102	Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization. *Journal of Cellular Physiology*, **2005**, 204, 227-35	7	41

101	Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa. *Journal of Cellular Physiology*, **2005**, 203, 457-64	7	238
100	Suppression and regression of choroidal neovascularization by polyamine analogues. *Investigative Ophthalmology and Visual Science*, **2005**, 46, 3323-30		25
99	Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein. *Molecular Pharmacology*, **2005**, 68, 1543-50	4.3	26
98	Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. *FASEB Journal*, **2005**, 19, 963-5	0.9	92
97	Supplemental oxygen improves diabetic macular edema: a pilot study. *Investigative Ophthalmology and Visual Science*, **2004**, 45, 617-24		151
96	Deficiency of neuropilin 2 suppresses VEGF-induced retinal neovascularization. *Molecular Medicine*, **2004**, 10, 12-8	6.2	47
95	Identification of gene expression changes associated with the progression of retinal degeneration in the rd1 mouse. *Investigative Ophthalmology and Visual Science*, **2004**, 45, 2929-42		79
94	Ocular neovascularisation and excessive vascular permeability. *Expert Opinion on Biological Therapy*, **2004**, 4, 1395-402	5.4	60
93	Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. *Investigative Ophthalmology and Visual Science*, **2004**, 45, 922-31		119
92	Changes in retinal pigment epithelial gene expression induced by rod outer segment uptake. *Investigative Ophthalmology and Visual Science*, **2004**, 45, 2098-106		18
91	Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation. *Journal of Biological Chemistry*, **2004**, 279, 19064-73	5.4	77
90	Intraocular gutless adenoviral-vectored VEGF stimulates anterior segment but not retinal neovascularization. *Journal of Cellular Physiology*, **2004**, 199, 399-411	7	17
89	Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. *Journal of Cellular Physiology*, **2004**, 199, 412-7	7	72
88	Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. *Journal of Cellular Physiology*, **2004**, 201, 393-400	7	76
87	Mouse model of post-surgical breakdown of the blood-retinal barrier. *Current Eye Research*, **2004**, 28, 421-6	2.9	13
86	A method for analysis of gene expression in isolated mouse photoreceptor and Müller cells. *Molecular Vision*, **2004**, 10, 366-75	2.3	31
85	Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. *FASEB Journal*, **2003**, 17, 896-8	0.9	108
84	Intraoperative ketorolac and eye pain after viteoretinal surgery: a prospective, randomized, placebo-controlled study. *Retina*, **2003**, 23, 8-13	3.6	17

83	Increased expression of brain-derived neurotrophic factor preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage. *Journal of Neuroscience*, **2003**, 23, 4164-72	6.6	114
82	Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. *Investigative Ophthalmology and Visual Science*, **2003**, 44, 3650-5		58
81	The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies. *Investigative Ophthalmology and Visual Science*, **2003**, 44, 3656-62		18
80	Topical nepafenac inhibits ocular neovascularization. *Investigative Ophthalmology and Visual Science* , **2003**, 44, 409-15		108
79	Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. *Circulation Research*, **2003**, 93, 1074-81	15.7	499
78	Photoreceptor-specific overexpression of platelet-derived growth factor induces proliferation of endothelial cells, pericytes, and glial cells and aberrant vascular development: an ultrastructural and immunocytochemical study. *Developmental Brain Research*, **2003**, 140, 169-83		16
77	Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. *Journal of Cellular Physiology*, **2003**, 195, 210-9	7	42
76	VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. *Journal of Cellular Physiology*, **2003**, 195, 241-8	7	214
75	Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. *Human Gene Therapy*, **2003**, 14, 129-41	4.8	83
74	Combined phacoemulsification, intraocular lens implantation, and vitrectomy for eyes with coexisting cataract and vitreoretinal pathology. *American Journal of Ophthalmology*, **2003**, 135, 291-6	4.9	122
73	In vivo micropathology of Best macular dystrophy with optical coherence tomography. *Experimental Eye Research*, **2003**, 76, 203-11	3.7	57
72	Gene expression variation in the adult human retina. *Human Molecular Genetics*, **2003**, 12, 2881-93	5.6	39
71	Identification of novel genes preferentially expressed in the retina using a custom human retina cDNA microarray. *Investigative Ophthalmology and Visual Science*, **2003**, 44, 3732-41		50
70	Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. *Investigative Ophthalmology and Visual Science*, **2003**, 44, 4989-93		76
69	RPE cells modulate subretinal neovascularization, but do not cause regression in mice with sustained expression of VEGF. *Investigative Ophthalmology and Visual Science*, **2003**, 44, 5430-7		34
68	Nitric oxide is proangiogenic in the retina and choroid. *Journal of Cellular Physiology*, **2002**, 191, 116-24	7	77
67	Angiopoietin-2 plays an important role in retinal angiogenesis. *Journal of Cellular Physiology*, **2002**, 192, 182-7	7	164
66	Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. *Human Gene Therapy*, **2002**, 13, 1305-16	4.8	34

65	Blockade of nitric-oxide synthase reduces choroidal neovascularization. *Molecular Pharmacology*, **2002**, 62, 539-44	4.3	38
64	Comparison between retinal thickness analyzer and optical coherence tomography for assessment of foveal thickness in eyes with macular disease. *American Journal of Ophthalmology*, **2002**, 134, 240-51	4.9	82
63	Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. *American Journal of Pathology*, **2002**, 160, 711-9	5.8	149
62	Gene therapy for retinal and choroidal diseases. *Expert Opinion on Biological Therapy*, **2002**, 2, 537-44	5.4	18
61	Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. *Developmental Cell*, **2002**, 3, 411-23	10.2	811
60	Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. *Investigative Ophthalmology and Visual Science*, **2002**, 43, 821-9		216
59	Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathies. *Investigative Ophthalmology and Visual Science*, **2002**, 43, 1610-5		28
58	AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. *Investigative Ophthalmology and Visual Science*, **2002**, 43, 1994-2000		165
57	Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy. *Investigative Ophthalmology and Visual Science*, **2002**, 43, 2001-6		49
56	Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. *Investigative Ophthalmology and Visual Science*, **2002**, 43, 2428-34		120
55	Quantitative assessment of the integrity of the blood-retinal barrier in mice. *Investigative Ophthalmology and Visual Science*, **2002**, 43, 2462-7		79
54	Identification of novel bovine RPE and retinal genes by subtractive hybridization. *Molecular Vision*, **2002**, 8, 251-8	2.3	6
53	Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. *Journal of Cellular Physiology*, **2001**, 188, 253-63	7	298
52	Expression and permeation properties of the K(+) channel Kir7.1 in the retinal pigment epithelium. *Journal of Physiology*, **2001**, 531, 329-46	3.9	56
51	Neurotrophic signaling in normal and degenerating rodent retinas. *Experimental Eye Research*, **2001** , 73, 693-701	3.7	62
50	Cloning and characterization of a human beta,beta-carotene-15,15Qdioxygenase that is highly expressed in the retinal pigment epithelium. *Genomics*, **2001**, 72, 193-202	4.3	143
49	Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. *American Journal of Pathology*, **2001**, 159, 313-20	5.8	138
48	Fibroblast growth factor-2 decreases hyperoxia-induced photoreceptor cell death in mice. *American Journal of Pathology*, **2001**, 159, 1113-20	5.8	72

47	Eye pain after vitreoretinal surgery: a prospective study of 185 patients. *Retina*, **2001**, 21, 627-32	3.6	42
46	Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. *Journal of Cellular Physiology*, **2000**, 184, 275-84	7	141
45	Retinal and choroidal neovascularization. *Journal of Cellular Physiology*, **2000**, 184, 301-10	7	315
44	Cell injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina. *Journal of Cellular Physiology*, **2000**, 185, 135-42	7	45
43	Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. *American Journal of Pathology*, **2000**, 157, 995-1005	5.8	72
42	Platelet-derived growth factor-A-induced retinal gliosis protects against ischemic retinopathy. *American Journal of Pathology*, **2000**, 156, 477-87	5.8	28
41	Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. *American Journal of Pathology*, **2000**, 156, 697-707	5.8	301
40	Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization **2000**, 184, 275		3
39	Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. *Documenta Ophthalmologica*, **1999**, 97, 217-28	2.2	114
38	Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. *Journal of Cellular Biochemistry*, **1999**, 74, 135-143	4.7	147
37	Hyperoxia causes decreased expression of vascular endothelial growth factor and endothelial cell apoptosis in adult retina. *Journal of Cellular Physiology*, **1999**, 179, 149-56	7	80
36	Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. *American Journal of Pathology*, **1999**, 154, 1743-53	5.8	156
35	A splice variant of trkB and brain-derived neurotrophic factor are co-expressed in retinal pigmented epithelial cells and promote differentiated characteristics. *Brain Research*, **1998**, 789, 201-12	3.7	26
34	Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. *American Journal of Pathology*, **1998**, 153, 757-65	5.8	84
33	Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. *American Journal of Pathology*, **1998**, 153, 1641-6	5.8	279
32	Transcriptional regulation of cellular retinaldehyde-binding protein in the retinal pigment epithelium. A role for the photoreceptor consensus element. *Journal of Biological Chemistry*, **1998**, 273, 5591-8	5.4	23
31	Double-labeling for Keratin and Class III β-Tubulin Within Cultured Retinal Pigment Epithelial Cells: Comparison of Chromogens to Yield Maximum Resolution of Two Structural Proteins Within The Same Cell. *Journal of Histotechnology*, **1997**, 20, 19-25	1.3	6
30	Dominant inheritance of optic pits. *American Journal of Ophthalmology*, **1997**, 124, 112-3	4.9	41

29	Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. *Experimental Eye Research*, **1997**, 64, 505-17	3.7	220
28	Neurotrophic factors, cytokines and stress increase expression of basic fibroblast growth factor in retinal pigmented epithelial cells. *Experimental Eye Research*, **1997**, 64, 865-73	3.7	46
27	Mammalian homolog of Drosophila retinal degeneration B rescues the mutant fly phenotype. *Journal of Neuroscience*, **1997**, 17, 5881-90	6.6	61
26	Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. *Journal of Neuroscience Research*, **1997**, 49, 268-80	4.4	127
25	Isoforms of platelet-derived growth factor and its receptors in epiretinal membranes: immunolocalization to retinal pigmented epithelial cells. *Experimental Eye Research*, **1995**, 60, 607-19	3.7	57
24	Class III beta-tubulin in human retinal pigment epithelial cells in culture and in epiretinal membranes. *Experimental Eye Research*, **1995**, 60, 385-400	3.7	50
23	Immunohistochemical localization of blood-retinal barrier breakdown sites associated with post-surgical macular oedema. *The Histochemical Journal*, **1994**, 26, 655-65		35
22	Corneal endothelial cell matrix promotes expression of differentiated features of retinal pigmented epithelial cells: implication of laminin and basic fibroblast growth factor as active components. *Experimental Eye Research*, **1993**, 57, 539-47	3.7	78
21	Evolution of morphologic changes after intravitreous injection of gentamicin. *Current Eye Research*, **1993**, 12, 521-9	2.9	15
20	Endophthalmitis Following Cataract Surgery. *Seminars in Ophthalmology*, **1993**, 8, 130-135	2.4	
19	Cytokine production by retinal pigmented epithelial cells. *International Review of Cytology*, **1993**, 146, 75-82		48
18	Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium. *The Histochemical Journal*, **1993**, 25, 648-63		39
17	Ultrastructural localization of RPE-associated epitopes recognized by monoclonal antibodies in human RPE and their induction in human fibroblasts by vitreous. *Graefes Archive for Clinical and Experimental Ophthalmology*, **1993**, 231, 395-401	3.8	5
16	Candidal endophthalmitis after lithotripsy of renal calculi. *Southern Medical Journal*, **1992**, 85, 773-4	0.6	6
15	Human retinal pigment epithelial cells possess V1 vasopressin receptors. *Current Eye Research*, **1991**, 10, 811-6	2.9	16
14	Thrombin is a stimulator of retinal pigment epithelial cell proliferation. *Experimental Eye Research*, **1991**, 53, 95-100	3.7	11
13	Spontaneous involution of subfoveal neovascularization. *American Journal of Ophthalmology*, **1990**, 109, 668-75	4.9	35
12	Human retinal pigment epithelial cells in culture possess A2-adenosine receptors. *Brain Research*, **1989**, 492, 29-35	3.7	37

11	Prevention or moderation of some ultrastructural changes in the RPE and retina of galactosemic rats by aldose reductase inhibition. *Experimental Eye Research*, **1989**, 49, 495-510	3.7	16
10	Retinal pigment epithelial cells produce a latent fibrinolytic inhibitor that is antigenically and biochemically related to type 1 plasminogen activator inhibitor produced by vascular endothelial cells. *Experimental Eye Research*, **1989**, 49, 195-203	3.7	22
9	Retinal pigment epithelial cells produce PDGF-like proteins and secrete them into their media. *Experimental Eye Research*, **1989**, 49, 217-27	3.7	103
8	Human retinal pigment epithelial cells possess muscarinic receptors coupled to calcium mobilization. *Brain Research*, **1988**, 446, 11-6	3.7	42
7	Progressive ultrastructural damage and thickening of the basement membrane of the retinal pigment epithelium in spontaneously diabetic BB rats. *Experimental Eye Research*, **1988**, 46, 545-58	3.7	25
6	Implication of protein carboxymethylation in retinal pigment epithelial cell chemotaxis. *Ophthalmic Research*, **1988**, 20, 54-9	2.9	7
5	High glucose concentrations inhibit protein synthesis in retinal pigment epithelium in vitro. *Experimental Eye Research*, **1987**, 44, 951-8	3.7	2
4	Characterization of adenylate cyclase in human retinal pigment epithelial cells in vitro. *Experimental Eye Research*, **1987**, 44, 471-9	3.7	31
3	A retina-derived stimulator(s) of retinal pigment epithelial cell and astrocyte proliferation. *Experimental Eye Research*, **1986**, 43, 449-57	3.7	15
2	Excitatory amino acid analogs evoke release of endogenous amino acids and acetyl choline from chick retina in vitro. *Vision Research*, **1985**, 25, 1375-86	2.1	28
1	The dissociation of evoked release of [3H]-GABA and of endogenous GABA from chick retina in vitro. *Experimental Eye Research*, **1984**, 39, 299-305	3.7	17